Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo - 19/06/20
Abstract |
Background |
Chronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life.
Objective |
To describe dupilumab effectiveness and tolerability in treating adult patients with CNPG refractory to both topical and systemic therapies.
Methods |
Retrospective, multicenter study including adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks.
Results |
Twenty-seven CNPG patients showed clinical improvement in terms of skin lesions, itch, sleeplessness, and quality of life. A consistent proportion of patients (24/27; 88.9%) had at least 16-week continuous treatment and achieved Investigator Global Assessment score 1 (11/24; 45.8%). An increased number of patients achieved at least a 2-grade reduction in Investigator Global Assessment score (19/24; 79.2%). Numeric rating scale values for itch and sleeplessness decreased from 8.9 to 2.7 and from 8.2 to 1.7, respectively (P < .001) after 16-week therapy. Ten patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy.
Limitations |
Major limitations included lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period.
Conclusion |
Dupilumab was proven effective in reducing itch and improving CNPG skin lesions.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, dupilumab, itch, nodular prurigo
Abbreviations used : CNPG, DLQI, IGA, IL, NRS, SD
Plan
Funding sources: None. |
|
Conflicts of interest: Dr Chiricozzi served as speaker and advisory board member for Sanofi Genzyme, dupilumab manufacturer. Drs Maurelli, Gori, Argenziano, De Simone, Calabrese, Girolomoni, and Peris have no conflicts of interest to declare. |
|
IRB approval status: Reviewed and approved by Fondazione Policlinico Universitario Agostino Gemelli IRCCS–Università Cattolica del Sacro Cuore, Prot 24169/19-0040941/19; ID: 2605. |
|
Reprints not available from the authors. |
Vol 83 - N° 1
P. 39-45 - juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?